[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Eulji University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":122},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,70,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100626846","timing-of-subcostal-tapb-combined-with-rectus-sheath-block-for-postoperative-pain-after-laparoscopic-cholecystectomy-100626846",false,"NCT07440940","Timing of Subcostal TAPB Combined With Rectus Sheath Block for Postoperative Pain After Laparoscopic Cholecystectomy","Effect of Timing of Ultrasound-Guided Subcostal Transversus Abdominis Plane Block Combined With Rectus Sheath Block on Postoperative Pain in Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Elective laparoscopic cholecystectomy\n* Adults aged 18 to 80 years\n* Ability to understand the study procedures and provide informed consent\n* American Society of Anesthesiologists (ASA) physical status I-III\n\nExclusion Criteria:\n\n* Presence of significant pain unrelated to the target disease that may interfere with pain assessment\n* Known allergy or contraindication to study medications (ropivacaine, acetaminophen, nefopam, or pethidine)\n* Planned single-port laparoscopic cholecystectomy\n* American Society of Anesthesiologists (ASA) physical status IV or higher\n* Infection of the abdominal wall or skin at the injection site, or anatomical abnormalities of the abdominal wall\n* Major neurological, psychiatric, or systemic diseases that may affect pain perception, treatment response, or study evaluation\n* Requirement for postoperative mechanical ventilation\n* Pregnancy or breastfeeding\n* Considered unsuitable for the study by the investigator\n* Refusal to participate or inability to provide informed consent","ALL","18 Years","80 Years",{"count":20,"type":21},96,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective randomized controlled trial aims to evaluate whether the timing of ultrasound-guided subcostal transversus abdominis plane (TAP) block combined with rectus sheath block (RSB) affects postoperative pain in patients undergoing laparoscopic cholecystectomy.\n\nParticipants will be randomly assigned to receive the combined regional blocks either before surgical incision or after completion of surgery. The primary outcome is postoperative pain intensity measured using a numerical rating scale. Secondary outcomes include opioid consumption, incidence of postoperative nausea and vomiting, and other recovery parameters.\n\nThe results of this study may help optimize the timing of abdominal wall blocks to improve postoperative analgesia and recovery following laparoscopic cholecystectomy.",[27,28],"Postoperative Pain","Laparoscopic Cholecystectomy",[28,30,31,32],"Transversus Abdominis Plane Block","Rectus Sheath Block","Postoperative pain","RECRUITING","2026-02-25",{"date":36,"type":37},"2026-02-27","ACTUAL",{"date":39,"type":37},"2026-02-23",{"date":41,"type":21},"2027-01-15",{"name":43,"class":44},"Eulji University Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100322253","a-major-determinant-focused-on-the-ecg-or-echocardiogram-for-picm-and-its-clinical-outcome-picm-syndrome-100322253","NCT03475498","A Major Determinant Focused on the ECG or Echocardiogram for PICM and Its Clinical Outcome (PICM Syndrome)","A Major Determinant Focused on the ECG or Echocardiogram for Pacing-induced Cardiomyopathy (PICM) and Its Clinical Outcome (PICM Syndrome) : Prospective, Multi-center, Observational Cohort Study.","Inclusion Criteria: mandatory (1 and 2) and optional (3 or 4)\n\n1. Willng to participate in the study and able to sign informed consent\n2. Undertaken ECG and echocardiogram including strain before and after device implantation\n\nExclusion Criteria:\n\n1. Less than 18 years of age\n2. Being pregnant or plan to become pregnant\n3. Advanced heart failure waiting in heart transplantation\n4. Have a life expectancy of less than 1 year","20 Years",{"count":55,"type":21},1000,"10 Years","OBSERVATIONAL","Chronic right ventricular pacing has a deleterious effect on left ventricular (LV) function, namely pacing-induced cardiomyopathy (PICM). Several parametes make difference of effect on the occurrence of PICM and its subsequent clinical outcomes. In particular, recognition of a major determinant focused on the ECG or echocardiographic parameters including strain or genetic factor for occurrence of PICM may lead to better identification of patients at high risk. Investigators prospectively enroll a participant with documented high risk of PICM and clinically follow-up to idenify clinical impact of PICM (PICM syndrome) over a long period of time.",[60],"Pacemaker Complication","2025-09-28",{"date":63,"type":37},"2025-10-02",{"date":65,"type":37},"2018-01-30",{"date":67,"type":21},"2028-02-28",{"name":43,"class":44},3,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100600121","lma-vs-high-flow-nasal-oxygen-during-ect-in-obese-patients-100600121","NCT07093372","LMA vs High-flow Nasal Oxygen During ECT in Obese Patients","Comparison Between Laryngeal Mask and High-flow Nasal Oxygen Therapy in Obese Patients Undergoing Electroconvulsive Therapy","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients scheduled to undergo ≥ 4 electroconvulsive therapy (ECT) sessions\n* Body mass index (BMI) ≥ 30 kg\u002Fm² (WHO obesity classification)\n* American Society of Anesthesiologists (ASA) physical status class I to III\n* Provided written informed consent (by patient or legal guardian)\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Patients with ASA class IV or V\n* Patients with anticipated dental injury risk that precludes use of a laryngeal mask airway\n* Patients or guardians who refuse participation","19 Years",{"count":79,"type":21},25,[24],"This study aims to compare two oxygenation strategies-laryngeal mask airway (LMA) ventilation and high-flow nasal cannula (HFNC)-during electroconvulsive therapy (ECT) in obese patients. Due to their physiological characteristics, obese patients are at increased risk of hypoxia during ECT under general anesthesia.\n\nAdult patients with a body mass index (BMI) ≥30 who are scheduled to undergo ECT will participate. Each participant will receive both oxygenation strategies in a fixed alternating order during four consecutive ECT sessions. The procedures will follow standard anesthesia protocols.\n\nDuring the ECT procedures and the 30-minute recovery period in the post-anesthesia care unit, we will monitor the occurrence of hypoxia (SpO₂ \\\u003C92%), ventilator parameters, vital signs, postoperative confusion within 24 hours, and any reports of dental discomfort. This information will help assess the safety and clinical utility of each oxygenation method for obese patients receiving ECT.",[83,84],"Electroconvulsive Therapy Treated Patients","Obesity",[86,87,88],"electroconvulsive therapy","obesity","ventilation strategy","NOT_YET_RECRUITING","2025-07-23",{"date":92,"type":37},"2025-07-30",{"date":94,"type":21},"2025-08-01",{"date":96,"type":21},"2026-07-31",{"name":43,"class":44},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":45},"100561480","perioperative-polmacoxib-reduce-opioid-consumption-for-post-operative-pain-after-rotator-cuff-tear-100561480","NCT06590714","Perioperative Polmacoxib Reduce Opioid Consumption for Post Operative Pain After Rotator Cuff Tear.","Inclusion Criteria:\n\n* patients over 18 years of age\n* Patients who need rotator cuff rupture or rotator cuff surgery with MRI identified osteoarthritis (especially small and medium SST dominant rupture)\n* NSAIDs unadministered patients for more than 1 month\n* Ultracet unadministered patients for more than 1 month\n\nExclusion Criteria:\n\n* primary fiftieth shoulder\n* including short-lived frozen shoulders\n* infectious arthritis\n* previous corticosteroid injections\u002Fsurgery\n* moderate-severe arthroplasty\n* a traumatized patient\n* a central or peripheral nervous system disease\n* a mental illness that may not conform to medical or physical therapy\n* a woman of childbearing age\n* Pregnancy\n* a severe gastrointestinal ulcer",{"count":105,"type":21},150,[24],"1. \\*\\*One day (±1 day) before surgery:\\*\\* The investigator or designated study staff will thoroughly explain the clinical trial process to the participant and their guardian (representative) based on the informed consent form and provide the form so that all participants and their guardians have sufficient time to read, discuss, and decide. Participants who agree to participate in the clinical trial will voluntarily sign the written consent form and receive a copy of the signed consent form before any study-related procedures are conducted. The clinical trial site will assign a screening number to patients who voluntarily provide consent and undergo screening. The screening number can be assigned in the order in which the participants sign the consent within the study site. After confirming eligibility based on inclusion\u002Fexclusion criteria, randomization will be performed to assign participants to either the treatment group or the control group (with a 1:1 ratio). If assigned to the treatment group, participants will receive \\'Polacoxib (preventive Acelex cap 2mg) once daily, NSAIDs-excluded non-opioid\u002Fopioid analgesics - PRN use.\\' If assigned to the control group, participants will receive NSAIDs-excluded non-opioid or opioid analgesics. Data will be collected by comparing the two groups in a double-arm setup. Pain scores, UCLA\u002FASES scores, and joint range of motion will be collected, and this data will be valid up to 3 months before the surgery. (For patients taking NSAIDs or Ultracet, the dose will be maintained until v5.)\n2. \\*\\*Two hours before surgery:\\*\\* Administration of medication begins.\n3. \\*\\*Three days after surgery:\\*\\* Collect pain scores and the cumulative number of NSAIDs-excluded non-opioid or opioid analgesic doses (post-surgery). Non-opioid or opioid analgesics (e.g., Fentanyl injection or Ultracet) will be used to manage post-surgical pain, and the number of doses will be collected to assess the participant's pain.\n4. \\*\\*Two weeks after surgery:\\*\\* An outpatient visit will be conducted one week after discharge. Collect pain scores and the cumulative number of NSAIDs-excluded non-opioid or opioid analgesic doses at the two-week mark.\n5. \\*\\*Six weeks after surgery:\\*\\* Collect pain scores and the cumulative number of NSAIDs-excluded non-opioid or opioid analgesic doses.\n6. \\*\\*Three months after surgery:\\*\\* MRI will be performed to check for re-tears (optional for participants). This visit will be the study's completion visit, during which pain scores, UCLA\u002FASES scores, joint range of motion, and cumulative doses of NSAIDs-excluded non-opioid or opioid analgesics will be collected. If adverse events occurring during the treatment period have resolved before this completion visit, no additional safety follow-up will be performed, and this visit will be considered the end of the clinical trial. If adverse events have not resolved by the completion visit, follow-up will continue until the adverse events have either returned to pre-study or baseline levels, or the principal investigator or designee determines that the adverse events have stabilized, or no further follow-up is deemed necessary. This follow-up will mark the completion of the clinical trial.",[109],"Rotator Cuff Tear",[111,112,113],"rotator cuff tear","reduction of Opioids","Effects of Polmacoxib Administration","2024-09-06",{"date":116,"type":37},"2024-09-19",{"date":118,"type":37},"2024-08-23",{"date":120,"type":21},"2025-08-31",{"name":43,"class":44},""]